Search This Blog

Tuesday, December 24, 2024

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million

 Achilles Therapeutics has sold certain technology assets to drug giant AstraZeneca for $12 million following a review of strategic alternatives by the clinical-stage biopharmaceutical company.

Achilles on Tuesday said the deal includes transfer of the proprietary data and samples from the TRACERx non-small cell lung cancer study and the London company's material acquisition platform to AstraZeneca.

Achilles in September said it would implement cost-cutting measures, including a workforce reduction, and launch a review of its options after ending development of its TIL-based cNeT therapy and ending a pair of clinical trials.

The company on Tuesday said it plans to undertake additional measures, including a further workforce reduction and a decrease in the size of its board, while remaining compliant with Nasdaq and Securities and Exchange Commission requirements.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/Achilles-Therapeutics-Sells-Technology-Assets-to-AstraZeneca-for-12-Million-48651240/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.